248 related articles for article (PubMed ID: 36644131)
1. Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer.
Hirose T; Yamamoto S; Kato K
Therap Adv Gastroenterol; 2023; 16():17562848221148250. PubMed ID: 36644131
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.
Yamamoto K; Yamamoto S; Kato K
Expert Opin Drug Saf; 2024 Jun; 23(6):667-675. PubMed ID: 38676380
[TBL] [Abstract][Full Text] [Related]
3. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S; Kato K
Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
[TBL] [Abstract][Full Text] [Related]
5. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Kim Y; Yamamoto S; Kato K
Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
7. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Sakata T; Yatsuzuka N; Doi T; Kato K
Esophagus; 2022 Oct; 19(4):683-692. PubMed ID: 35668304
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for the treatment of advanced esophageal cancer.
Harada K; Yamamoto S; Kato K
Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
11. Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma.
Ogura N; Yamamoto S; Kato K
Expert Opin Biol Ther; 2024 Jun; ():1-7. PubMed ID: 38860728
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncology for esophageal cancer.
Yamamoto S; Kato K
Future Oncol; 2020 Nov; 16(32):2673-2681. PubMed ID: 32777942
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.
Högner A; Thuss-Patience P
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33673374
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
18. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.
Muro K; Kojima T; Moriwaki T; Kato K; Nagashima F; Kawakami H; Ishihara R; Ogata T; Satoh T; Iwakami K; Han S; Yatsuzuka N; Takami T; Bhagia P; Doi T
Esophagus; 2022 Jan; 19(1):137-145. PubMed ID: 34591237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
